Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

47
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
47
Phase II Reactions: Glucuronidation01:24

Phase II Reactions: Glucuronidation

294
Glucuronidation, a pivotal phase II biotransformation process, involves the coupling of glucuronic acid to a drug or xenobiotic. Given its widespread occurrence and critical role in drug metabolism, it's considered the most crucial phase II reaction. It enhances the water solubility of substances, aiding their expulsion from the body. The driving force behind these reactions is a group of enzymes known as UDP-glucuronosyltransferases (UGTs). UGTs facilitate the transfer of a glucuronic acid...
294
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

235
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
235
Drug Metabolism: Phase II Reactions01:14

Drug Metabolism: Phase II Reactions

3.7K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.7K
Phase II Conjugation Reactions: Overview01:14

Phase II Conjugation Reactions: Overview

159
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
159
Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters00:54

Noncompartmental Analysis: Miscellaneous Pharmacokinetic Parameters

65
The noncompartmental approach is a widely used method in pharmacokinetics to assess drugs' behaviors in the body. It considers several factors, including clearance, bioavailability, and total volume of distribution.
One key aspect of the noncompartmental approach is determining a drug's total clearance. This can be done by dividing the drug dose by the area under the concentration-time curve from zero to infinity. The area under the concentration-time curve represents the drug's...
65

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Drug-Drug Interaction Potential Between the Oral Antibiotic Zoliflodacin and the CYP3A4 Inhibitor Itraconazole: A Phase 1 Study in Healthy Participants.

Clinical and translational science·2026
Same author

Evaluation of an <i>in vivo</i> pulmonary aspergillosis model for triazole susceptibility breakpoint development.

Antimicrobial agents and chemotherapy·2026
Same author

Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections.

Antimicrobial agents and chemotherapy·2025
Same author

Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia.

Antimicrobial agents and chemotherapy·2025
Same author

Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.

Antimicrobial agents and chemotherapy·2024
Same author

<i>In vivo</i> pharmacodynamic characterization of a next-generation polyene, SF001, in the invasive pulmonary aspergillosis mouse model.

Antimicrobial agents and chemotherapy·2024

Related Experiment Video

Updated: Jun 7, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.6K

Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.

Anthony P Cammarata1, M Courtney Safir1, Michael Trang1

  • 1Institute for Clinical Pharmacodynamics, Inc., Schenectady, New York, USA.

Antimicrobial Agents and Chemotherapy
|November 21, 2024
PubMed
Summary

A population pharmacokinetic model for sulbactam-durlobactam was developed. This model aids in understanding drug behavior in patients, including effects of renal function and hemodialysis, for treating Acinetobacter pneumonia.

Keywords:
Phase 1Phase 2Phase 3durlobactampopulation pharmacokineticssulbactamsulbactam–durlobactam

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

12.8K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K

Related Experiment Videos

Last Updated: Jun 7, 2025

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

14.6K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

12.8K
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
10:44

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures

Published on: March 28, 2017

9.8K

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Infectious Diseases
  • Drug Development

Background:

  • Sulbactam-durlobactam is approved for hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus.
  • Understanding the pharmacokinetic profile is crucial for optimizing treatment efficacy and safety.

Purpose of the Study:

  • To develop a population pharmacokinetic (PK) model for sulbactam-durlobactam in plasma.
  • To evaluate the impact of covariates, including renal function and hemodialysis, on drug exposure.
  • To characterize drug penetration into epithelial lining fluid (ELF).

Main Methods:

  • Population PK modeling using data from 432 subjects and 8,100 plasma concentrations across Phase 1-3 studies.
  • Development of sub-models for hemodialysis (HD) and epithelial lining fluid (ELF) penetration.
  • Assessment of covariates including body weight, BMI, infection type, region, and renal function.

Main Results:

  • A four-compartment PK model with linear kinetics was established, accurately describing drug disposition.
  • Hemodialysis reduced the daily area under the concentration-time curve (AUC0-24) by approximately 30%.
  • Epithelial lining fluid penetration ratios were 41.3% for durlobactam and 86.0% for sulbactam; renal function was the only clinically relevant covariate.

Conclusions:

  • A robust population PK model for sulbactam-durlobactam was successfully developed.
  • The model provides a foundation for model-based simulations and pharmacokinetic-pharmacodynamic assessments.
  • Understanding PK variability, especially related to renal function, is key for optimizing therapy in Acinetobacter pneumonia.